ENDRA Life Sciences Inc. NDRA
corporation in 2007. We are developing a next-generation enhanced ultrasound technology platform—Thermo- Acoustic Enhanced
Ultrasound, or TAEUS®.
commercialization of TAEUS is a solution for the assessment of liver fat, a key biomarker associated with metabolic diseases,
including metabolic dysfunction-associated steatotic liver disease ("MASLD") and metabolic dysfunction-associated
Last close
4.80
2026-10-23
Market cap
$7.2M
2026-06-30 share count
52-week range
2.96 - 6.95
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-8.93
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $6.2K | $351.6K | $515.6K |
| Cost of revenue | — | — | — | — | — | $0 | $0 | $0 | $172.8K | — |
| Gross profit | — | — | — | — | — | $0 | $0 | $6.2K | $178.8K | $279.7K |
| R&D | $1.8M | $3.2M | $5.0M | $6.6M | $5.5M | $5.9M | $6.6M | $4.7M | $1.9M | $495.4K |
| SG&A | $3.7M | $7.1M | $4.7M | $5.2M | $4.9M | $5.0M | $3.9M | $3.8M | $2.8M | $1.5M |
| Total operating expenses | $5.8M | $10.8M | $10.5M | $13.2M | $11.5M | $11.5M | $10.8M | $9.0M | $4.8M | $2.1M |
| Operating income | -$5.8M | -$10.8M | -$10.5M | -$13.2M | -$11.5M | -$11.5M | -$10.8M | -$9.0M | -$4.6M | -$1.8M |
| Interest expense | — | — | — | — | — | — | — | — | $42.6K | $72.0K |
| Pre-tax income | -$7.0M | -$11.5M | -$10.1M | -$13.2M | -$11.2M | -$11.7M | -$13.3M | -$9.8M | -$5.4M | -$2.8M |
| Income tax | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.0M | -$11.5M | -$10.1M | -$13.2M | -$11.2M | -$11.7M | -$13.3M | -$9.8M | -$5.4M | -$2.8M |
| EPS, basic | -8.93 | -56.94 | — | -4.56 | -5.55 | -0.63 | — | — | — | — |
| EPS, diluted | -8.93 | -56.94 | -2,766.85 | — | — | -0.63 | -2.34 | -2.17 | -1.95 | -3.84 |
| Shares, diluted (wtd. avg.) | 787,020 | 202,106 | 3,636 | — | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $762.4K | $3.2M | $2.8M | $4.9M | $9.5M | $7.2M | — | — | — | — |
| Receivables | — | — | — | — | — | — | — | $0 | $6.8K | $0 |
| Inventory | $0 | $0 | $2.6M | $2.6M | $1.3M | $589.6K | $113.4K | $59.4K | $191.7K | $40.1K |
| Total current assets | $968.0K | $3.4M | $3.0M | $5.4M | $12.1M | $8.2M | $6.5M | $6.9M | $5.9M | $195.6K |
| Property, plant and equipment | $42.5K | $69.3K | $111.8K | $235.7K | $131.1K | $212.2K | $236.3K | $273.2K | $241.5K | $295.2K |
| Total assets | $3.9M | $4.5M | $6.8M | $9.3M | $12.9M | $8.8M | $7.2M | $7.2M | $6.1M | $490.8K |
| Accounts payable | $383.0K | $269.7K | $360.4K | $614.0K | $791.1K | $402.9K | $1.3M | $631.5K | $780.3K | $227.7K |
| Short-term debt | — | $0 | $28.5K | $28.5K | — | — | — | — | — | — |
| Total current liabilities | $751.0K | $605.2K | $903.1K | $1.7M | $1.5M | $986.7K | $2.1M | $974.6K | $848.2K | $1.4M |
| Long-term debt | — | $0 | $0 | $0 | $546.6K | — | — | — | — | — |
| Total liabilities | $1.6M | $1.9M | $1.1M | $2.1M | $2.1M | $1.6M | $2.4M | $974.6K | $848.2K | $1.4M |
| Retained earnings | -$110.5M | -$103.4M | -$91.9M | -$81.9M | -$68.7M | -$57.3M | -$45.2M | -$27.7M | -$17.9M | -$12.5M |
| Total equity | $2.3M | $2.6M | $5.7M | $7.2M | $10.8M | $7.2M | $4.8M | $6.2M | $5.3M | -$893.8K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.2M | -$7.4M | -$9.5M | -$12.8M | -$11.1M | -$10.7M | -$8.6M | -$7.7M | -$3.3M | -$1.3M |
| Depreciation and amortisation | $44.0K | $46.5K | $123.7K | $96.7K | $116.2K | $99.3K | $80.6K | $68.3K | $61.5K | $64.9K |
| Stock-based compensation | $329.4K | $571.9K | $996.4K | $1.2M | $1.4M | $2.1M | — | — | — | — |
| Capital expenditure | $17.3K | $16.0K | $33.9K | $202.6K | $45.0K | $75.3K | $43.6K | $100.0K | $7.9K | — |
| Investing cash flow | -$3.0M | -$12.8K | -$24.7K | -$202.6K | -$45.0K | -$75.3K | -$43.6K | -$100.0K | -$7.9K | $0 |
| Financing cash flow | $5.7M | $7.8M | $7.5M | $8.4M | $13.4M | $11.9M | $8.3M | $8.7M | $8.8M | $1.4M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-037617.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $515.6K | $351.6K | $6.2K | $0 | $0 | — | — | — | — | — |
| Gross profit | $279.7K | $178.8K | $6.2K | $0 | $0 | — | — | — | — | — |
| Net income | -$2.8M | -$5.4M | -$9.8M | -$13.3M | -$11.7M | -$11.2M | -$13.2M | -$10.1M | -$11.5M | -$7.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Change of control Control of the company has changed hands. Item 5.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3845
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MDT | Medtronic plc | $122.04B | 25.6x | 8.4% |
| LIVN | LivaNova PLC | $4.46B | — | 10.7% |
| ITGR | Integer Holdings Corp | $4.30B | 43.8x | 8.0% |
| TMDX | TransMedics Group, Inc. | $2.45B | 14.5x | 37.1% |
| AXGN | Axogen, Inc. | $2.05B | — | 20.2% |
| BLFS | BIOLIFE SOLUTIONS INC | $1.89B | — | 28.9% |
| CNMD | CONMED Corp | $1.48B | 32.6x | 5.2% |
| CBLL | Ceribell, Inc. | $1.04B | — | 36.1% |